Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus

Michael Mullerad; David P. Eisenberg; Timothy J. Akhurst; Prasad S. Adusumilli; Christopher C. Riedl; Amit Bhargava; Mithat Gonen; Ronald Finn; Peter T. Scardino; Yuman Fong

doi:10.1007/s11307-005-0028-x

Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus

Michael Mullerad, David P. Eisenberg, Timothy J. Akhurst, Prasad S. Adusumilli, Christopher C. Riedl, Amit Bhargava, Mithat Gonen, Ronald Finn, Peter T. Scardino, Yuman Fong

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

Original language	English (US)
Pages (from-to)	30-35
Number of pages	6
Journal	Molecular Imaging and Biology
Volume	8
Issue number	1
DOIs	https://doi.org/10.1007/s11307-005-0028-x
State	Published - Jan 2006
Externally published	Yes

Keywords

Fluorodeoxyglucose
Herpes virus
Hormonal therapy
Prediction

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11307-005-0028-x

Cite this

@article{067df582944048ebb9dd11b3b64d8150,

title = "Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus",

abstract = "Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.",

keywords = "Fluorodeoxyglucose, Herpes virus, Hormonal therapy, Prediction",

author = "Michael Mullerad and Eisenberg, {David P.} and Akhurst, {Timothy J.} and Adusumilli, {Prasad S.} and Riedl, {Christopher C.} and Amit Bhargava and Mithat Gonen and Ronald Finn and Scardino, {Peter T.} and Yuman Fong",

note = "Funding Information: This study was supported in part by grant ROI CA 75416 from the National Institutes of Health, grant IMG0402501 from the Susan G. Komen Foundation, grant R25-CA96945 from the National Cancer Institute, and grant BC024118 from the US Army. The radiotracer was prepared in a facility constructed with support from Research Facilities Improvement Program Grant number C06 RR-11192.",

year = "2006",

month = jan,

doi = "10.1007/s11307-005-0028-x",

language = "English (US)",

volume = "8",

pages = "30--35",

journal = "Molecular Imaging and Biology",

issn = "1536-1632",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus

AU - Mullerad, Michael

AU - Eisenberg, David P.

AU - Akhurst, Timothy J.

AU - Adusumilli, Prasad S.

AU - Riedl, Christopher C.

AU - Bhargava, Amit

AU - Gonen, Mithat

AU - Finn, Ronald

AU - Scardino, Peter T.

AU - Fong, Yuman

N1 - Funding Information: This study was supported in part by grant ROI CA 75416 from the National Institutes of Health, grant IMG0402501 from the Susan G. Komen Foundation, grant R25-CA96945 from the National Cancer Institute, and grant BC024118 from the US Army. The radiotracer was prepared in a facility constructed with support from Research Facilities Improvement Program Grant number C06 RR-11192.

PY - 2006/1

Y1 - 2006/1

N2 - Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

AB - Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes enhance oncolytic viral replication and improve efficacy in the treatment of androgen-dependent prostate cancer cell line. Imaging of changes in 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake by positron emission tomography (PET) is a sensitive method of detecting altered cellular metabolism involved in cancer therapy. We therefore hypothesized that FDG-PET can predict tumor response to oncolytic HSV therapy. In this study, androgen increased cell kill (74%) in vitro and enhanced viral yield (2.4-fold) in vivo following HSV therapy. This enhanced efficacy was predicted by high FDG accumulation in intact animals compared to low FDG uptake following orchiectomy (p = 0.002). This proof-of-concept study provides the mechanistic basis for selecting patients for targeted oncolytic viral therapy by means of a noninvasive molecular imaging method in the treatment of prostate cancer.

KW - Fluorodeoxyglucose

KW - Herpes virus

KW - Hormonal therapy

KW - Prediction

UR - http://www.scopus.com/inward/record.url?scp=33645807822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645807822&partnerID=8YFLogxK

U2 - 10.1007/s11307-005-0028-x

DO - 10.1007/s11307-005-0028-x

M3 - Article

C2 - 16362150

AN - SCOPUS:33645807822

SN - 1536-1632

VL - 8

SP - 30

EP - 35

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

IS - 1

ER -

Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this